SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- Gen-Probe
Incorporated (Nasdaq: GPRO) announced today that Patrick Sullivan, former chairman, president and
chief executive officer of Cytyc Corporation, has been elected to
its board of directors. Gen-Probe's board now has 10 members,
including eight independent directors.
"We are delighted that Pat has agreed to join Gen-Probe's
already strong board," said Hank
Nordhoff, the Company's chairman. "We expect to
benefit greatly from his experiences leading a multi-billion-dollar
growth company, and from his deep knowledge of diagnostics and
women's health."
Mr. Sullivan, 58, joined Cytyc in 1991 as vice president, sales
and marketing. He became president, CEO and a director in
1994, and added the chairman's title in 2002. He remained in
those roles until the company's merger with Hologic in 2007.
Mr. Sullivan now leads Constitution Medical Investors, a
Boston-based private investment
firm in partnership with Warburg Pincus, and is also a director of
PerkinElmer. He graduated with distinction from the
U.S. Naval Academy and earned an
M.B.A., also with distinction, from Harvard
University.
About Gen-Probe
Gen-Probe Incorporated is a global leader in the development,
manufacture and marketing of rapid, accurate and cost-effective
molecular diagnostic products and services that are used primarily
to diagnose human diseases, screen donated human blood, and ensure
transplant compatibility. Gen-Probe has approximately 27
years of expertise in nucleic acid testing (NAT), and received the
2004 National Medal of Technology, America's highest honor for
technological innovation, for developing NAT assays for blood
screening. Gen-Probe is headquartered in San Diego and employs approximately 1,300
people. For more information, go to www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations,
beliefs, plans, objectives, assumptions, future events or
performance are not historical facts and are forward-looking
statements. These statements are often, but not always, made
through the use of words or phrases such as believe, will, expect,
anticipate, estimate, intend, plan and would. Forward-looking
statements are not guarantees of performance. They involve
known and unknown risks, uncertainties and assumptions that may
cause actual results to differ materially from those expressed or
implied. Some of the risks, uncertainties and assumptions
that could cause actual results to differ materially from estimates
or projections in the forward-looking statement include, but are
not limited to, the risk that Gen-Probe may not be able to retain
its key employees and directors. For additional information
about risks and uncertainties we face and a discussion of our
financial statements and footnotes, see documents we have filed
with the SEC, including our Annual Report on Form 10-K for the
fiscal year ended December 31, 2009,
and all subsequent periodic reports. We assume no obligation
and expressly disclaim any duty to update any forward-looking
statement to reflect events or circumstances after the date of this
press release or to reflect the occurrence of subsequent
events.
|
|
Contact:
Michael Watts
Vice president, investor
relations and corporate communications
858-410-8673
|
|
|
|
|
|
|
SOURCE Gen-Probe Incorporated
Copyright . 20 PR Newswire